Next Science Details Cash Position and Capital Return Plan After Asset Sale

Next Science Ltd ( (AU:NXS) ) just unveiled an update.

Next Science has reported a closing cash balance of US$35.2 million and no debt as at 31 December 2025, following the sale of substantially all of its assets to OSARTIS GmbH for US$50 million in September. The company is seeking shareholder approval at an extraordinary general meeting on 28 January 2026 to distribute approximately US$28 million (about A$0.145 per share) to investors as a capital return, estimating total net proceeds to shareholders of around US$30 million after adjustments and liabilities, with the initial payment expected on 12 February 2026. The December quarter cashflows mainly reflect sale-related costs, transition services and the closure of its US operations, resulting in net operating cash outflows of US$3.8 million, while senior executives, including the CEO and CFO, stepped down at year-end as the transition services agreement concluded, underscoring the company’s wind-down and shift towards returning capital to shareholders.

The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

More about Next Science Ltd

Next Science Limited is an Australian-listed company that, until recently, developed and commercialised anti-infective medical technologies. In September 2025, it completed the sale of substantially all of its assets and those of its wholly owned subsidiaries to German medical company OSARTIS GmbH and has since applied to be removed from the official list of the ASX, effectively transitioning away from its previous operating business structure.

Average Trading Volume: 525,971

Technical Sentiment Signal: Sell

Current Market Cap: A$42.43M

Find detailed analytics on NXS stock on TipRanks’ Stock Analysis page.